Tokyo Tape
Sign in
← Sakai Chemical Industry

Half-year report · Q2

4078.TEDINET S100UO2I
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed

Amended by S100V7D8 (2025-02-07).

Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥41.9bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥82.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥40.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥2.6bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥917m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥2.6bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥3.1bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥885m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥2.4bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥773m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.0bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.8bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥121.2bnat 2024-09-30Cons.Assets
Total assets¥125.4bnat 2024-03-31Cons.Assets
Total assets¥131.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥44.1bnat 2024-09-30Cons.Liabilities
Total liabilities¥50.0bnat 2024-03-31Cons.Liabilities
Net assets / equity¥77.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥75.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥80.7bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥14.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥16.6bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥14.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥16.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥15.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.2bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥7.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥6.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥3.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥4.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥107.712024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-437.652023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-125.532023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥97.232024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio62.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio59.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.5%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥910m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥910m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.2bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2024-04-01 → 2024-09-30¥38.4bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2024-04-01 → 2024-09-30¥37.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥798m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.8bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2024-04-01 → 2024-09-30¥4.4bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2024-04-01 → 2024-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥111m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2024-04-01 → 2024-09-30¥65m
—segment totalrevenue2024-04-01 → 2024-09-30¥42.8bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥41.9bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥910m
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.8bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2023-04-01 → 2023-09-30¥36.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥36.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥498m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2023-04-01 → 2023-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2023-04-01 → 2023-09-30¥144m
—segment totalrevenue2023-04-01 → 2023-09-30¥41.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥40.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥635m
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 516
ItemContextValueUnit
Gross profitPrior1YTDDuration7875000000JPY
Gross profitCurrentYTDDuration9632000000JPY
Selling general and administrative expensesPrior1YTDDuration6958000000JPY
Selling general and administrative expensesCurrentYTDDuration7006000000JPY
Operating incomePrior1YTDDuration917000000JPY
Operating incomeCurrentYTDDuration2626000000JPY
Interest income noiPrior1YTDDuration4000000JPY
Interest income noiCurrentYTDDuration12000000JPY
Dividends income noiPrior1YTDDuration78000000JPY
Dividends income noiCurrentYTDDuration107000000JPY
Foreign exchange gains noiPrior1YTDDuration324000000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Subsidy income noiPrior1YTDDuration－JPY
Subsidy income noiCurrentYTDDuration50000000JPY
Other noiPrior1YTDDuration30000000JPY
Other noiCurrentYTDDuration55000000JPY
Non operating incomePrior1YTDDuration437000000JPY
Non operating incomeCurrentYTDDuration225000000JPY
Interest expenses noePrior1YTDDuration53000000JPY
Interest expenses noeCurrentYTDDuration67000000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration79000000JPY
Tender offer related expenses noePrior1YTDDuration342000000JPY
Tender offer related expenses noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration73000000JPY
Other noeCurrentYTDDuration71000000JPY
Non operating expensesPrior1YTDDuration469000000JPY
Non operating expensesCurrentYTDDuration218000000JPY
Ordinary incomePrior1YTDDuration885000000JPY
Ordinary incomeCurrentYTDDuration2633000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration0JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration0JPY
Gain on sales of investment securities eiPrior1YTDDuration43000000JPY
Gain on sales of investment securities eiCurrentYTDDuration50000000JPY
Extraordinary incomePrior1YTDDuration44000000JPY
Extraordinary incomeCurrentYTDDuration51000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration98000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration60000000JPY
Impairment loss elPrior1YTDDuration57000000JPY
Impairment loss elCurrentYTDDuration204000000JPY
Other elPrior1YTDDuration－JPY
Other elCurrentYTDDuration3000000JPY
Extraordinary lossPrior1YTDDuration156000000JPY
Extraordinary lossCurrentYTDDuration267000000JPY
Income before income taxesPrior1YTDDuration773000000JPY
Income before income taxesCurrentYTDDuration2416000000JPY
Income taxesPrior1YTDDuration2569000000JPY
Income taxesCurrentYTDDuration608000000JPY
Profit lossPrior1YTDDuration-1796000000JPY
Profit lossCurrentYTDDuration1808000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass